---
schema_version: "secwatch.filing_event.v1"
accession: "0001828185-24-000083"
form_type: "8-K"
ticker: "BRNS"
cik: "0001828185"
company_name: "Barinthus Biotherapeutics plc."
filed_at: "2024-11-06T23:59:59+00:00"
generated_at: "2026-05-30T04:46:45.258086+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Barinthus Bio Q3 net loss narrows to $8.1M on $15M Vaxzevria royalty revenue; cash runway into Q2 2026

## Summary
- Net loss of $8.1M ($0.21/sh) vs $16.9M ($0.43/sh) in Q2; revenue of $15.0M from AstraZeneca Vaxzevria royalty share.
- Cash and equivalents $106.1M at Sep 30, 2024, down from $117.8M at Jun 30; cash runway now into Q2 2026.
- HBV003 trial of VTP-300 in chronic hepatitis B fully enrolled (121 participants); updated data at AASLD Nov 2024 as late-breaking abstracts.
- VTP-1000 Phase 1 AVALON trial in celiac disease initiated; VTP-850 Phase 1 PCA001 trial completed enrollment (22 participants).

## SEC filing metadata
- accession: 0001828185-24-000083
- form_type: 8-K
- ticker: BRNS
- cik: 0001828185
- company_name: Barinthus Biotherapeutics plc.
- filed_at: 2024-11-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1828185/000182818524000083/0001828185-24-000083-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1828185/000182818524000083/brns-20241106.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001828185-24-000083
- JSON: https://secwatch.observer/filing/0001828185-24-000083.json
- Plain text: https://secwatch.observer/filing/0001828185-24-000083.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.